Release date: 2016-09-28
At the 25th week of the establishment of Neusoft Group, Neusoft Group Chairman and CEO Liu Jiren revealed to the 21st Century Business Herald that the Neusoft Medical Equity Delivery has been completed and the listing preparation work is basically ready, and the capital platform will be better developed in the future. It is also known that Neusoft Medical will no longer be included in the consolidated financial statements of Neusoft Group from July 31.
For the future development, Neusoft Medical CEO Wu Shaojie said in an interview with the 21st Century Business Herald that in the context of the country's continuous promotion of domestic medical equipment development, Neusoft Medical has reorganized its strategic goals in the past two years, after new shareholders have come in. Opened a second venture , in the future, Neusoft Medical will increase investment in research and development, and will expand the overseas market layout.
Domestic substitution
In the late 1980s, large domestic medical equipment relied entirely on imports. It is in this context that the opportunity to repair CT by chance has led Neusoft Group, which started with software, to start cross-border medical care.
It is understood that when Neusoft medical products were introduced to the domestic market, the imported medical equipment with the same model was sold at a price of not less than 4 million yuan. After Neusoft Medical entered the market, the price of domestic CT products fell by about 30%. .
Imported medical equipment prices have remained high for many years. For example , the "2013 China Medical Device Blue Book" released by China Pharmaceuticals (600056, shares) material association shows that the price of imported medical equipment is generally higher than the original country of Europe, America and Japan 50%-100%. Another market source pointed out that the current high-end medical equipment sector represented by "GPS" (General Electric GE, Philips Philips, Siemens Siemens) accounted for more than 90% of the market share of 20%.
In this regard, Wu Shaojie pointed out that this is the result of long-term lack of domestic brands, rooted in the lack of core technology and brand competitiveness of domestic high-end medical equipment companies.
In response to this situation, the state has also begun to introduce relevant policies.
In August 2014, the National Health and Family Planning Commission stated that it will “focus on promoting the use of domestic medical equipment in the top three hospitalsâ€; in August 2016, the Ministry of Industry and Information Technology announced the “Notice on Printing and Implementing Five Major Projects for Manufacturing Innovation Centers,†High-performance medical devices are among the 11 key areas of high-end equipment innovation projects in the five major projects. On September 18th, the Ministry of Industry and Information Technology and the State Health Planning Commission jointly held a conference on promoting the development of domestic medical equipment, demanding to improve the market competitiveness of domestic medical equipment and speed up the pace of “going out†of domestically produced equipment.
With the encouragement of related policies and the increased investment in research and development by domestic enterprises, the share of domestically produced equipment, including CT, is gradually rising. According to industry statistics, domestic equipment in the MR market share in 2014 accounted for 22%, and in 2015 it rose to 44%. Domestic equipment in the CT market accounted for 9% market share in 2014 and rose to 28% in 2015.
In this regard, Xu Ming, vice president of the China Chamber of Commerce for Import and Export of Medicines and Health Products , believes that the “import substitution†of the medical device industry is the general trend. "From the policy level, the government encourages domestic equipment to be preferred in local bidding; from the perspective of market behavior, with the improvement of corporate competitiveness, domestic enterprises have already achieved import substitution in some areas."
However, an industry veteran pointed out to the 21st Century Business Herald reporter that the state now encourages the development of domestic medical device enterprises, and frequently promotes favorable policies, such as requiring public hospitals to purchase domestically produced equipment, but the habits of imported equipment have long been used, and some domestically produced The experience of medical devices is not good, causing a lot of pressure on hospitals and doctors.
At the same time, China's medical device companies still have small and scattered characteristics. Xu Ming pointed out that at present, medical device companies with a true scale and output value of more than 20 million yuan account for less than 20%. According to CFDA statistics, as of the end of November 2015, there were 14,151 medical device companies nationwide.
Wu Shaojie admits that medical equipment companies do not have a certain scale of support, the stability and refinement of products must be affected, which also causes problems for clinicians, and even affects the use of word of mouth for the entire domestic equipment. "In the case of nuclear magnetic resonance, the world only provides "GPS" for nuclear magnetic resonance plus Toshiba, and there are no fewer than 15 magnetic resonance manufacturers in China. How can there be such a large market to support so many magnetic resonance manufacturers in China?"
"We also hope that the domestically-funded equipment enterprises supported by the state can become bigger and stronger, and truly make high-quality medical equipment. The national policy is only a window for domestic enterprises, whether it can really enter, but also from clinical use, Functional, stability, after-sales service and many other aspects and multinational companies PK." Wu Shaojie told 21st Century Business Herald.
Neusoft Medical's second venture
Neusoft Medical has also aimed at the development of the international market while continuously breaking through the monopoly in China. In 2002, Neusoft Medical CT was exported to Turkey for the first time. In 2003, it entered the North American market. In 2015, Neusoft Medical successfully launched the first 128-slice CT with completely independent intellectual property rights in China, and quickly entered the international market.
Today, Neusoft Medical has produced products all over the country and sold to 109 countries and regions around the world, providing medical equipment products and services to more than 9,000 medical institutions around the world. With the breakthrough of this high-end product, the Neusoft medical listing plan, which is mainly engaged in research and development of imaging equipment such as CT, has also been put on the agenda.
In December 2014, Neusoft Group announced that Hony Capital, Goldman Sachs, Neusoft Holdings and other investors spent 1.6 billion yuan to increase the capital of Neusoft Medical, and purchased a certain proportion of Neusoft Medical from Neusoft Group for RMB 1.133 billion. Equity, also set up equity incentives for Neusoft medical management team and key employees.
According to the announcement, Neusoft Group completed the first and second related capital increase and delivery and equity transfer procedures of Neusoft Medical in September 2015 and July 2016 respectively. On July 29, the new board of directors of Neusoft Medical began as the highest authority. With the exercise of powers, Neusoft Group no longer has control of Neusoft Medical, and Neusoft Group will no longer include Neusoft Medical in the consolidated financial statements of the company as of July 31, 2016.
For the listing of Neusoft Medical, Liu Jiren told the 21st Century Business Herald that this is actually the second venture of Neusoft Medical. I hope that the capital platform can help Neusoft Medical to develop better and is also a kind of entrepreneur. excitation.
It is understood that in the future, with the help of capital, Neusoft Medical will increase its R&D investment, expand its market share at home and abroad, and accelerate its development through more acquisitions and mergers to supplement production lines and business lines.
Wu Shaojie said that Neusoft Medical has been far higher than the industry average in research and development investment. In 2015, R&D investment accounted for up to 14% of revenue. In the future, R&D centers will be established in Beijing, Shanghai and Guangzhou outside Shenyang; In terms of investment, the scope of investment involves CT, magnetic resonance, ultrasound, X-ray, RT, PaiCT and other fields, as well as the development and acquisition of IVD (in vitro diagnostic products).
The above-mentioned insiders pointed out that under the help of capital, Neusoft's "secondary venture" will better carry out market layout and breakout. It is worth noting that with the introduction of policies such as grading medical treatment, in addition to the top three hospitals, the current war has already burned to the primary medical market, and the demand for high-end medical equipment in hospitals at the county level and below has also attracted “GPSâ€. In the competition, they also developed economical CT to gradually penetrate.
Source: 21st Century Business Herald
Fish Series
Seafood Mix,Cooked Mussel Meat,Mussel Half Shell,Cut Swimming Crab
GOLD STAR FISHERY ZHOUSHAN CO.,LTD. , https://www.goldstar-aquatic.com